These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32972190)

  • 41. Undiagnosed acromegaly as an underlying cause of sudden death.
    Borgen AE; Bugge ABD; Lund EL; Banner J
    Forensic Sci Med Pathol; 2021 Jun; 17(2):322-326. PubMed ID: 33847875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acromegaly, inflammation and cardiovascular disease: a review.
    Wolters TLC; Netea MG; Riksen NP; Hermus ARMM; Netea-Maier RT
    Rev Endocr Metab Disord; 2020 Dec; 21(4):547-568. PubMed ID: 32458292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.
    Gadelha MR; Kasuki L; Lim DST; Fleseriu M
    Endocr Rev; 2019 Feb; 40(1):268-332. PubMed ID: 30184064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics and treatment outcomes of micromegaly - acromegaly with apparently normal basal GH: A retrospective study and literature review.
    Inacio I; Fonseca L; Amado A; Benido V; Ribeiro I; Dores J; Amaral C; Cardoso MH
    Endocr Regul; 2022 Apr; 56(2):87-94. PubMed ID: 35489048
    [No Abstract]   [Full Text] [Related]  

  • 47. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.
    Puglisi S; Ferraù F; Ragonese M; Spagnolo F; Cannavò S
    Front Endocrinol (Lausanne); 2020; 11():28. PubMed ID: 32117056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options.
    Goldberg MD; Vadera N; Yandrapalli S; Frishman WH
    Cardiol Rev; 2018; 26(6):307-311. PubMed ID: 29794808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acromegaly or chronic renal failure: a diagnostic dilemma.
    Wong NA; Ahlquist JA; Camacho-Hübner C; Goodwin CJ; Dattani M; Marshall NJ; Wass JA
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):221-6. PubMed ID: 9135706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment.
    García-Álvarez M; Climent V
    Minerva Endocrinol; 2019 Jun; 44(2):159-168. PubMed ID: 30482010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects.
    Colao A; Marzullo P; Spiezia S; Ferone D; Giaccio A; Cerbone G; Pivonello R; Di Somma C; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1986-91. PubMed ID: 10372698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is growth hormone good for the heart?
    Silverman BL; Friedlander JR
    J Pediatr; 1997 Jul; 131(1 Pt 2):S70-4. PubMed ID: 9255233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suppressed levels of growth hormone and insulin-like growth factor-1 during successful pregnancy in persistent acromegaly.
    Shimatsu A; Usui T; Tagami T; Kuzuya H; Takahashi JA
    Endocr J; 2010; 57(6):551-3. PubMed ID: 20371983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly.
    Powlson AS; Gurnell M
    Neuroendocrinology; 2016; 103(1):75-85. PubMed ID: 26227953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-mediated "pseudoacromegaly".
    Sam AH; Tan T; Meeran K
    Hormones (Athens); 2011; 10(2):156-61. PubMed ID: 21724541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5 Long-term acromegaly and associated cardiovascular complications: a case-based review.
    Colao A
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S31-8. PubMed ID: 20129192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Acromegaly and pregnancy: report of six new cases].
    Persechini ML; Gennero I; Grunenwald S; Vezzosi D; Bennet A; Caron P
    J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):704-12. PubMed ID: 24035359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.